

**Table 4** Current Clinical Trials in MOGAD and Related Neuroimmunological Disorders

NCT Number	Study Title	Acronym	Study Status	Conditions	Interventions	Primary Outcome Measures	Enrollment	Phases
NCT06452537	Safety and Efficacy of Tocilizumab in Patients With MOGAD	TOMATO	Recruiting	MOGAD	DRUG: Tocilizumab DRUG: Prednisone	Time from randomization to the first MOGAD relapse as determined by an adjudication committee	102	PHASE2/3
NCT06474520	Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease	CBSinIIDD	Not Yet Recruiting	Idiopathic Inflammatory Demyelinating Disease, MS, NMOSD	DRUG: Calculus bovis sativus (CBS)	Modified Rankin Scale (mRS) within 12 weeks after treatment initiation	250	NA
NCT06541626	Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases		Not Yet Recruiting	MS, NMOSD,MOGAD		Relapse, Long-term neurological function assessed using the EDSS	450	OBSERVATIONAL
NCT05271409	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease	Meteoroid	Not Yet Recruiting	MOGAD	DRUG: Satralizumab, OTHER: Placebo	Time from randomization to the first occurrence of a MOGAD relapse in the DB treatment period	152	PHASE3
NCT05204459	MS-ResearchBiomarkerS	MS-ReBS	Recruiting	MS, NADs, Healthy Aging		Identifying risk factors for disability progression	1000	
NCT05063162	A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With MOGAD	cosMOG	Recruiting	MOGAD	DRUG: Rozanolixizumab, OTHER: Placebo	Time from randomization to first independently centrally adjudicated relapse	104	PHASE3
NCT04561557	Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	CARTinNS	Recruiting	Autoimmune Diseases of the Nervous System	BIOLOGICAL: CT103A cells, DRUG: Cyclophosphamide and fludarabine	Types and incidence of dose-limiting toxicity (DLT)	36	EARLY PHASE1

NCT06443333	National, Multicentric Registry Study on Neuroimmunological Diseases in China	NIDBase	Recruiting	MS, NMO, Myasthenia Gravis	Data collection and follow-up observation	Annual recurrence rate	7000	N/A
NCT06280755	Clinical Impact Through AI-assisted MS Care	RECLAIM	Not Yet Recruiting	MS, NMO	N/A	Data contribution	7000	N/A
NCT05605951	Acute Optic Neuritis Network	ACON	Recruiting	MS,NMO	Non-interventional study	Visual outcomes	200	N/A
NCT05545384	Immediate vs Delayed Treatment in Anti-MOG Syndromes	IDAR	Not Yet Recruiting	Acute Demyelinating Syndrome	Azathioprine, Rituximab	Annualized relapse rate	86	Phase 2/3
NCT05349006	Azathioprine in MOGAD	MOGwAI	Not Yet Recruiting	MOGAD	Azathioprine, Placebo	Time to first relapse	126	Phase 3

This table summarizes ongoing and planned clinical trials pertinent to Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and related neuroimmunological disorders. It encompasses 12 trials, including interventional studies evaluating novel therapeutics such as tocilizumab, satralizumab, and rozanolixizumab, as well as observational studies and registries. The trials span various phases, from early Phase 1 to Phase 3, and include both adult and pediatric populations. Key information provided includes NCT numbers, study titles, acronyms, enrollment targets, and primary outcome measures. This comprehensive overview offers insights into the current landscape of MOGAD research, highlighting emerging treatment strategies and efforts to enhance understanding of disease progression and management.